OpenAI's GPT-Rosalind agents surface new drug discovery lead for neurodegenerative disease

OpenAI · x · 2026-11-21

OpenAI, working with PerturbAI and Scripps Research, detailed a concrete output from GPT-Rosalind in drug discovery.

A representative AI-for-Science case where models generate actionable drug discovery hypotheses.

Original post →

More from Companies & People

Companies & People channel →